Portal de Periódicos da CAPES

Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023

2024; Centers for Disease Control and Prevention; Volume: 30; Issue: 6 Linguagem: Inglês

10.3201/eid3006.231454

1080-6059

Ryo Kinoshita, Shô Miyamoto, Shoko Sakuraba, Jun Sugihara, Motoi Suzuki, Tadaki Suzuki, Daisuke Yoneoka,

SARS-CoV-2 detection and testing

We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).